Department of Obstetrics and Gynaecology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, CA, The Netherlands.
Department of Obstetrics and Gynaecology, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
J Psychosom Obstet Gynaecol. 2024 Dec;45(1):2330414. doi: 10.1080/0167482X.2024.2330414. Epub 2024 Mar 21.
The first-trimester anomaly scan (FTAS) has the potential to detect major congenital anomalies in an early stage of pregnancy. Due to this potential early detection, there is a trend to introduce FTAS in regular care. Data regarding the impact of FTAS on the patient's perspective are limited.
To provide an overview of the literature assessing the impact of the FTAS on health-related quality of life (HRQoL) and healthcare costs.
Literature search was performed in Embase, PubMed, Medline Ovid, Cochrane Library database, Web-of-Science, and Google Scholar were searched. All studies that reported the performance of a nuchal translucency measurement with a basic fetal assessment HRQoL or healthcare costs of FTAS were included. Studies solely describing screening of chromosomal anomalies were excluded. Three authors independently screened the studies and extracted the data. Results were combined using descriptive analysis. PROSPERO registration number: CRD42016045190.
The search yielded 3242 articles and 16 were included. Thirteen articles (7045 pregnancies) examined the relationship between FTAS and HRQoL. Anxiety scores were raised temporarily before FTAS and returned to early pregnancy baseline following the absence of anomalies. Depression scores did not change significantly as a result of FTAS. Three articles studied healthcare costs. These studies, published before 2005, found a combination of FTAS and second-trimester anomaly scan (STAS) resulted in an increased amount of detected anomalies when compared to a STAS-only regimen. However, the combination would also be more costly.
Women experience anxiety in anticipation of the FTAS result and following a reassuring FTAS result, anxiety returns to the baseline level. FTAS seems to be a reassuring experience. The included studies on costs showed the addition of FTAS is likely to increase the number of detected anomalies against an increase in healthcare costs per pregnancy.Review registration: PROSPERO CRD42016045190.
早孕期异常扫描（FTAS）有可能在妊娠早期发现重大先天性异常。由于这种早期检测的潜力，在常规护理中引入 FTAS 的趋势正在出现。关于 FTAS 对患者视角的影响的数据有限。
提供评估 FTAS 对健康相关生活质量（HRQoL）和医疗保健成本影响的文献综述。
在 Embase、PubMed、Medline Ovid、Cochrane 图书馆数据库、Web-of-Science 和 Google Scholar 上进行文献检索。所有报告颈项透明层测量与基本胎儿评估 HRQoL 或 FTAS 医疗保健成本表现的研究均被纳入。仅描述染色体异常筛查的研究被排除在外。三位作者独立筛选研究并提取数据。结果采用描述性分析进行合并。PROSPERO 注册号：CRD42016045190。
搜索结果产生了 3242 篇文章，其中 16 篇被纳入。13 篇文章（7045 例妊娠）研究了 FTAS 与 HRQoL 之间的关系。在 FTAS 之前，焦虑评分暂时升高，在没有异常的情况下，焦虑评分恢复到早孕基线。FTAS 并未导致抑郁评分显著变化。三篇文章研究了医疗保健成本。这些发表于 2005 年之前的研究发现，FTAS 与第二次妊娠中期异常扫描（STAS）相结合，与仅进行 STAS 相比，检测到的异常数量增加。然而，联合治疗也会更昂贵。
女性在期待 FTAS 结果和在得到 reassuring FTAS 结果后会感到焦虑，之后焦虑会回到基线水平。FTAS 似乎是一种令人安心的体验。关于成本的纳入研究表明，FTAS 的增加可能会增加每例妊娠的检测异常数量，同时增加医疗保健成本。
PROSPERO CRD42016045190。
